During a discussion on the next frontier of medicine for cold agglutinin disease, stakeholders react to the rationale for studying newer, novel complement-targeted therapies. Neil Minkoff, MD: Let me ...

Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolysis that is caused by activation of the classic complement pathway. Sutimlimab, a humanized monoclonal antibody, ...

A panel of clinicians and payers highlight challenges that impact the treatment of a rare autoimmune hemolytic anemia, cold agglutinin disease. Neil Minkoff, MD: We started talking about how it used ...

Imagine not being able to stay outdoors during winter. Or having to put on gloves to open the fridge. New knowledge and better treatment give hope to people who suffer from a rare cold disease. For ...

Sutimlimab is an IgG4 monoclonal antibody that inhibits the classical complement pathway. The Food and Drug Administration (FDA) has approved Enjaymo™ (sutimlimab-jome) to decrease the need for red ...

Cold agglutinin disease (CAD) is a rare subtype of autoimmune haemolytic anaemia (AIHA) where autoantibodies, predominantly of the IgM class, bind to red blood cells at reduced temperatures. This ...

Please provide your email address to receive an email when new articles are posted on . Research presented at ASH Annual Meeting and Exposition provided an exciting update on many of the ...

Sutimlimab is an investigational monoclonal antibody designed to stop hemolysis by selectively inhibiting C1s in the classical complement pathway. The Food and Drug Administration (FDA) has issued a ...

In a recent case report published in the Journal of Clinical Laboratory Analysis, researchers presented two cases to highlight the impact of cold agglutinin syndrome (CAS) on clinical presentations in ...

Dear P.W.: Cold agglutinin disease is a specific type of anemia where antibodies attack and destroy a person’s own red blood cells. Unlike the usual type of autoimmune hemolytic (”hemolytic” means ...

A new drug has become the first and only treatment for people with cold agglutinin disease (CAD) that is approved by the US Food and Drug Administration (FDA). The new product is sutimlimab-jome ...